Medications based on<unk> s are used in the treatment of diabetes mellitus type 2. Several long-lasting GLP-1 analogs having insulinotropic activity have been developed, and several, including dulaglutide (Trulicity), exenatide (Byetta), liraglutide (Victoza), semaglutide (Ozempic, Wegovy and Rybelsus) and exenatide extended-release (Bydureon), have been approved for use in the U.S. Another approach is to inhibit the enzyme that inactivates GLP-1 and GIP, DPP-4. Several DPP-4 inhibitors that can be taken orally as tablets have been developed.
Incretin
Histrelin
Somatostatin
Ghrelin
Nesfatin-1
Bryostatin
Gluten exorphin
Beta-Endorphin